Under the terms of the extension agreement, Shire shall continue as the Product Marketing Authorisation holder in the UK and Ireland and will be responsible for sales and distribution of the Calcichew® portfolio until 31st December 2013. Shire and Takeda will collaborate on the transition of activities during 2013, with Takeda taking responsibility for the promotion and marketing of the Calcichew® portfolio from 1st July 2013.
In January 2014, the Marketing Authorisations for the CALCICHEW® portfolio will transfer to Takeda in both countries (exact timing subject to regulatory approval) and the Trademarks relating to the Calcichew® portfolio in the two countries will be assigned to Takeda subject to the terms of the agreement. The financial arrangements related to this agreement have not been disclosed and remain confidential between Takeda and Shire.
“This is an exciting development for Takeda in the UK and Ireland” said Yasuhiro Fukutomi, Managing Director, Takeda UK and Cluster Lead for UK & Ireland. “The Calcichew® portfolio will add significant financial revenues to Takeda in the UK and Ireland and there is significant potential for growth in both countries. We have successfully repatriated other products to Takeda UK over the last 3 years and we will work to repeat this success with the Calcichew® portfolio. We look forward to working collaboratively with Shire to achieve a smooth transition that will ensure continued support and an uninterrupted product supply for healthcare professionals and patients”.